Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

169 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Screening for therapeutic trials and treatment indication in clinical practice: MACK-3, a new blood test for the diagnosis of fibrotic NASH.
Boursier J, Anty R, Vonghia L, Moal V, Vanwolleghem T, Canivet CM, Michalak S, Bonnafous S, Michielsen P, Oberti F, Iannelli A, Van Gaal L, Patouraux S, Blanchet O, Verrijken A, Gual P, Rousselet MC, Driessen A, Hunault G, Bertrais S, Tran A, Calès P, Francque S. Boursier J, et al. Among authors: moal v. Aliment Pharmacol Ther. 2018 May;47(10):1387-1396. doi: 10.1111/apt.14621. Epub 2018 Mar 25. Aliment Pharmacol Ther. 2018. PMID: 29577364 Clinical Trial.
FibroMeters: a family of blood tests for liver fibrosis.
Calès P, Boursier J, Oberti F, Hubert I, Gallois Y, Rousselet MC, Dib N, Moal V, Macchi L, Chevailler A, Michalak S, Hunault G, Chaigneau J, Sawadogo A, Lunel F. Calès P, et al. Among authors: moal v. Gastroenterol Clin Biol. 2008 Sep;32(6 Suppl 1):40-51. doi: 10.1016/S0399-8320(08)73992-7. Gastroenterol Clin Biol. 2008. PMID: 18973845 Free article.
Comparison of blood tests for liver fibrosis specific or not to NAFLD.
Calès P, Lainé F, Boursier J, Deugnier Y, Moal V, Oberti F, Hunault G, Rousselet MC, Hubert I, Laafi J, Ducluzeaux PH, Lunel F. Calès P, et al. Among authors: moal v. J Hepatol. 2009 Jan;50(1):165-73. doi: 10.1016/j.jhep.2008.07.035. Epub 2008 Oct 7. J Hepatol. 2009. PMID: 18977552 Free article. Clinical Trial.
Assessment of new hyaluronic acid assays and their impact on FibroMeter scores.
Veillon P, Gallois Y, Moal V, Fouchard-Hubert I, Charles I, Larcher F, Dib N, Boursier J, Oberti F, Laafi J, Guéchot J, Balan V, Calès P, Lunel-Fabiani F. Veillon P, et al. Among authors: moal v. Clin Chim Acta. 2011 Jan 30;412(3-4):347-52. doi: 10.1016/j.cca.2010.11.009. Epub 2010 Nov 12. Clin Chim Acta. 2011. PMID: 21075099
The CUPIC algorithm: an accurate model for the prediction of sustained viral response under telaprevir or boceprevir triple therapy in cirrhotic patients.
Boursier J, Ducancelle A, Vergniol J, Veillon P, Moal V, Dufour C, Bronowicki JP, Larrey D, Hézode C, Zoulim F, Fontaine H, Canva V, Poynard T, Allam S, De Lédinghen V; ANRS CO20 CUPIC Study Group. Boursier J, et al. Among authors: moal v. J Viral Hepat. 2015 Dec;22(12):1002-10. doi: 10.1111/jvh.12433. Epub 2015 Jul 27. J Viral Hepat. 2015. PMID: 26216230
Direct comparison of the specialised blood fibrosis tests FibroMeterV2G and Enhanced Liver Fibrosis score in patients with non-alcoholic fatty liver disease from tertiary care centres.
Guillaume M, Moal V, Delabaudiere C, Zuberbuhler F, Robic MA, Lannes A, Metivier S, Oberti F, Gourdy P, Fouchard-Hubert I, Selves J, Michalak S, Peron JM, Cales P, Bureau C, Boursier J. Guillaume M, et al. Among authors: moal v. Aliment Pharmacol Ther. 2019 Dec;50(11-12):1214-1222. doi: 10.1111/apt.15529. Epub 2019 Oct 15. Aliment Pharmacol Ther. 2019. PMID: 31617224
169 results